Scot Ebbinghaus
Merck & Co., Inc., Rahway, NJ, USA (United States)
1 paper in the Anchorcite directory, published in 2015, cited 6,034 times in total.
Research topics
- Cancer Immunotherapy and Biomarkers · 1 paper
- Cutaneous Melanoma Detection and Management · 1 paper
- Melanoma and MAPK Pathways · 1 paper
Frequent co-authors
- Caroline Robert · 1 paper
- Jacob Schachter · 1 paper
- Georgina Venetia Long · 1 paper
- Ana Maria Arance · 1 paper
- Jean‐Jacques Grob · 1 paper
- Laurent Mortier · 1 paper
- ADIL I. DAUD · 1 paper
- Matteo Salvatore Carlino · 1 paper
Papers
- Pembrolizumab versus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2015 · 6,034 citations
BACKGROUND: The immune checkpoint inhibitor ipilimumab is the standard-of-care treatment for patients with advanced melanoma. Pembrolizumab inhibits the programmed cell death 1 (PD-1) immune checkpoint and has antitumor activity in patients with advanced melanoma. METHODS: In this randomized, controlled, phase…
Metadata from OpenAlex (CC0).